MedTrace Logo

Comparison of Sirolimus and Azathioprine in Lung Transplantation

NCT00321906 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 181

Last updated 2016-09-21

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to compare the safety and effectiveness of two different anti-rejection drug regimens.

Conditions

  • Delayed Graft Function
  • Acute Graft Rejection

Interventions

DRUG

azathioprine

azathioprine 2mg/kg

DRUG

sirolimus

sirolimus 2-4mg daily

Sponsors & Collaborators

  • Astellas Pharma Inc

    collaborator INDUSTRY

  • Loyola University

    collaborator OTHER

  • University of Florida

    collaborator OTHER

  • University of Pennsylvania

    collaborator OTHER

  • Baylor College of Medicine

    collaborator OTHER

  • Ochsner Health System

    collaborator OTHER

  • Columbia University

    collaborator OTHER

  • University of Wisconsin, Madison

    collaborator OTHER

  • University of Chicago

    lead OTHER

Principal Investigators

  • Edward Garrity, MD · University of Chicago

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-04-30
Primary Completion
2011-08-31
Completion
2011-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00321906 on ClinicalTrials.gov